

Jeffrey L Cummings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1889933/publications.pdf>

Version: 2024-02-01

369
papers

68,044
citations

1994

101
h-index

767

249
g-index

389
all docs

389
docs citations

389
times ranked

51936
citing authors

#	ARTICLE	IF	CITATIONS
1	International Psychogeriatric Association (IPA) consensus for defining psychosis in major and mild neurocognitive disorders. <i>International Psychogeriatrics</i> , 2022, 34, 203-207.	1.0	2
2	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177.	0.8	33
3	Aducanumab: Appropriate use recommendations. <i>Alzheimer's and Dementia</i> , 2022, 18, 531-533.	0.8	28
4	The costs of developing treatments for Alzheimer's disease: A retrospective exploration. <i>Alzheimer's and Dementia</i> , 2022, 18, 469-477.	0.8	40
5	Disease modification is not all we need symptomatic therapies for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2022, 18, 3-4.	10.1	6
6	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	10.2	203
7	Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm) to Patients Participating in Clinical Trials. <i>Journal of Prevention of Alzheimer's Disease</i> , 2022, 9, 241-246.	2.7	0
8	Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 7.	6.2	42
9	Pimavanserin and dementia-related psychosis. <i>Lancet Neurology</i> , 2022, 21, 114-115.	10.2	0
10	Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5727-5757.	2.6	20
11	Aducanumab: Appropriate Use Recommendations Update. <i>Journal of Prevention of Alzheimer's Disease</i> , 2022, 9, 221-230.	2.7	41
12	Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem. , 2022, , 123-134.		0
13	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 214-223.	1.8	1
14	Financing Alzheimer's Disease Drug Development. , 2022, , 465-479.		1
15	ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development. , 2022, , 177-189.		0
16	The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program. , 2022, , 309-318.		0
17	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
18	Globalization of Alzheimer's Disease Clinical Trials. , 2022, , 275-280.		0

#	ARTICLE	IF	CITATIONS
19	The Use and Development of Clinical Measures of Alzheimer's Disease Trials. , 2022, , 281-291.		0
20	Introduction to Venture Capital in Alzheimer's Disease Drug Development. , 2022, , 524-532.		0
21	The Harrington Discovery Institute and Alzheimer's Disease Drug Development. , 2022, , 45-53.		0
22	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
23	Artificial Intelligence in Alzheimer's Drug Discovery. , 2022, , 62-72.		2
24	Role of Animal Models in Alzheimer's Disease Drug Development. , 2022, , 73-94.		0
25	Institutional Review Boards and Oversight of Alzheimer's Disease Trials. , 2022, , 429-436.		0
26	Alzheimer's Disease Clinical Trial Study Partners. , 2022, , 333-342.		0
27	Drug Development for Alzheimer's Disease: An Historical Perspective. , 2022, , 25-33.		0
28	Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development. , 2022, , 480-485.		0
29	Alzheimer's Disease Neuroimaging Initiative. , 2022, , 455-464.		1
30	Best Practices for Clinical Trials during COVID-19. , 2022, , 354-360.		0
31	Alzheimer's Disease Drug Development in Pharmaceutical Companies. , 2022, , 162-169.		0
32	Development of Fluid Biomarkers for Alzheimer's Disease. , 2022, , 361-374.		0
33	Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials. , 2022, , 232-248.		0
34	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 54.	6.2	24
35	Alzheimer's disease drug development pipeline: 2022. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12295.	3.7	271
36	Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment. Frontiers in Psychiatry, 2022, 13, 804168.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's™ disease with lecanemab, an anti-A β 2 protofibril antibody. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	4
38	Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	3.7	6
39	The role of basket trials in drug development for neurodegenerative disorders. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	7
40	Brain functional topology differs by sex in cognitively normal older adults. <i>Cerebral Cortex Communications</i> , 2022, 3, .	1.6	2
41	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021, 56, 70-85.	3.1	7
42	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 375-383.	1.2	36
43	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's™ Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 3-13.	1.8	17
44	A Brain Capital Grand Strategy: toward economic reimagination. <i>Molecular Psychiatry</i> , 2021, 26, 3-22.	7.9	41
45	Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". <i>Alzheimer's and Dementia</i> , 2021, 17, 702-703.	0.8	28
46	Alzheimer's disease drug development pipeline: 2021. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12179.	3.7	259
47	Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12106.	3.7	18
48	New approaches to symptomatic treatments for Alzheimer's™ disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 2.	10.8	96
49	Who funds Alzheimer's disease drug development?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12185.	3.7	7
50	Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-13.	2.7	115
51	AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's™ drug discovery. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 24.	6.2	44
52	Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. <i>Genome Research</i> , 2021, 31, 1900-1912.	5.5	53
53	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021, 96, 848-863.	1.1	149
54	A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's™ dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 62.	6.2	99

#	ARTICLE	IF	CITATIONS
55	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021, 96, 944-954.	1.1	14
56	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β 2 protofibril antibody. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 80.	6.2	380
57	Alzheimer's disease. <i>Lancet, The</i> , 2021, 397, 1577-1590.	13.7	1,530
58	Building brain capital. <i>Neuron</i> , 2021, 109, 1430-1432.	8.1	5
59	Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1649-1662.	2.6	11
60	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 98.	6.2	152
61	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology, The</i> , 2021, 20, 484-496.	10.2	396
62	Brain Health Living Labs. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 698-703.	1.2	3
63	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 309-319.	27.0	61
64	Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index. <i>Frontiers in Neurology</i> , 2021, 12, 605318.	2.4	2
65	Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease. <i>Neurology</i> , 2021, 97, 543-544.	1.1	28
66	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	10.1	144
67	Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. <i>Neurology and Therapy</i> , 2021, 10, 941-953.	3.2	12
68	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	2.6	15
69	Why aducanumab is important. <i>Nature Medicine</i> , 2021, 27, 1498-1498.	30.7	10
70	The Amyloid- β 2 Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	7.9	478
71	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 136.	6.2	30
72	Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12136.	3.7	12

#	ARTICLE	IF	CITATIONS
73	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. <i>Journal of Personalized Medicine</i> , 2021, 11, 14.	2.5	19
74	The Alzheimer's disease drug development landscape. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 186.	6.2	49
75	Development and assessment of a brief screening tool for psychosis in dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12254.	2.4	0
76	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 1175-1188.	11.6	87
77	Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401). <i>Touch Reviews in Neurology</i> , 2021, 17, 70.	0.2	0
78	Individual patient data meta-analysis assessing the adverse event profile of Alzheimer dementia randomized clinical trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
79	ICARE AD-US: Design of a prospective, single-arm, multicenter, noninterventional real-world study of aducanumab in the United States. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
80	Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
81	Development and assessment of a brief screening tool for psychosis in dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, e057766.	0.8	0
82	Affective Computing for Late-Life Mood and Cognitive Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 782183.	2.6	7
83	Pioglitazone reduces the incidence of Alzheimer's disease: From genetics to population-based validation. <i>Alzheimer's and Dementia</i> , 2021, 17, e051950.	0.8	0
84	Sleep disruption and disorders in former college and professional American football players. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
85	Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	3
86	Item-level analysis of clinical measures in patients with early symptomatic Alzheimer's disease following treatment with high-dose aducanumab in the phase 3 study EMERGE. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
87	Multimodal single-cell/nucleus RNA-sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e051952.	0.8	0
88	Brain Health Executives: A Transdisciplinary Workforce Innovation-A Commentary.. <i>Innovations in Clinical Neuroscience</i> , 2021, 18, 24-27.	0.1	4
89	Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 383-400.	1.2	57
90	Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 124-134.	2.3	3

#	ARTICLE	IF	CITATIONS
91	Unique white matter structural connectivity in early-stage drug-naïve Parkinson disease. <i>Neurology</i> , 2020, 94, e774-e784.	1.1	24
92	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	2.6	39
93	Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1256-1269.	1.2	40
94	Î2-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	6.2	16
95	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 1483-1492.	0.8	46
96	Association of plasma YKL-40 with brain amyloid-Î2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.1	18
97	Alzheimer's disease drug development pipeline: 2020. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12050.	3.7	353
98	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. <i>Medicinal Research Reviews</i> , 2020, 40, 2386-2426.	10.5	61
99	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. <i>Brain</i> , 2020, 143, 3816-3826.	7.6	41
100	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 661-673.	10.1	97
101	Repurposed agents in the Alzheimer's disease drug development pipeline. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 98.	6.2	45
102	Key developmental milestones for tau therapeutics. <i>Alzheimer's and Dementia</i> , 2020, 16, e044896.	0.8	0
103	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12098.	2.4	13
104	A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 547-557.	2.6	20
105	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 22-37.	1.5	5
106	An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home. <i>Frontiers in Psychiatry</i> , 2020, 11, 173.	2.6	11
107	Brain health INnovation Diplomacy: a model binding diverse disciplines to manage the promise and perils of technological innovation. <i>International Psychogeriatrics</i> , 2020, 32, 955-979.	1.0	24
108	The Neuropsychiatric Inventory: Development and Applications. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 73-84.	2.3	83

#	ARTICLE	IF	CITATIONS
109	Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12115.	3.7	6
110	THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE DRUG DEVELOPMENT PROGRAMS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-3.	2.7	1
111	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 68.	6.2	44
112	Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. <i>Current Psychiatry Reports</i> , 2019, 21, 79.	4.5	38
113	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 73.	6.2	20
114	A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 231-240.	3.7	18
115	Alzheimer's disease drug development pipeline: 2019. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 272-293.	3.7	546
116	ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-7.	2.7	48
117	Clinical drug development for dementia with Lewy bodies: past and present. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 951-965.	4.1	32
118	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	6.2	148
119	Sex Moderates Amyloid and Apolipoprotein β 4 Effects on Default Mode Network Connectivity at Rest. <i>Frontiers in Neurology</i> , 2019, 10, 900.	2.4	14
120	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	2.7	45
121	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 779-794.	2.6	336
122	Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 953-961.	2.6	36
123	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 164-174.	3.7	30
124	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1408-1420.	27.0	397
125	The Role of Biomarkers in Alzheimer's Disease Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 29-61.	1.6	84
126	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 109.	6.2	14

#	ARTICLE	IF	CITATIONS
127	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 303-313.	2.6	8
128	The National Institute on Aging's Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 172-178.	0.8	94
129	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S3-S22.	2.6	108
130	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	7.1	79
131	Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurology</i> , 2018, 17, 213-222.	10.2	131
132	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 130.	7.4	121
133	Alzheimer's disease drug development pipeline: 2018. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 195-214.	3.7	469
134	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1691-1703.	27.0	512
135	ABBY. <i>Neurology</i> , 2018, 90, e1889-e1897.	1.1	188
136	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	23
137	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , 2018, 11, 147-152.	3.1	224
138	PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSIS. <i>Journal of Prevention of Alzheimer's Disease</i> , 2018, 5, 1-6.	2.7	44
139	Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1223-1234.	2.6	39
140	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	7.7	370
141	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 116.	6.2	28
142	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 102.	6.2	24
143	Genetic Risk of Alzheimer's Disease: Three Wishes Now That the Genie is Out of the Bottle. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 421-423.	2.6	3
144	Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 79-89.	2.6	19

#	ARTICLE	IF	CITATIONS
145	Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 326-329.	3.7	3
146	The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 330-343.	3.7	62
147	Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 350-356.	3.7	11
148	Changes in regional cerebral blood flow associated with a 45-day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. Experimental Gerontology, 2018, 111, 118-121.	2.8	45
149	Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 173-181.	3.7	39
150	Statistical advances in clinical trials and clinical research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 366-371.	3.7	20
151	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. Journal of Alzheimer's Disease, 2017, 56, 929-938.	2.6	306
152	Alzheimer's disease drug development pipeline: 2017. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 367-384.	3.7	331
153	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2017, 57, 387-393.	2.6	11
154	Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 1-9.	3.7	17
155	On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
156	Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimer's Research and Therapy, 2017, 9, 72.	6.2	45
157	Disease modification and Neuroprotection in neurodegenerative disorders. Translational Neurodegeneration, 2017, 6, 25.	8.0	68
158	CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER'S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. Journal of prevention of Alzheimer's disease, The, 2017, 4, 1-8.	2.7	34
159	Drug Development in Alzheimer's Disease: The Role of Default Mode Network Assessment in Phase II. US Neurology, 2017, 13, 67.	0.2	8
160	Atypical Alzheimer's Disease, Mixed Dementia, and Amyloid Angiopathy. , 2017, , 39-47.		0
161	Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. CNS Neuroscience and Therapeutics, 2016, 22, 159-166.	3.9	95
162	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 993-999.	1.9	110

#	ARTICLE	IF	CITATIONS
163	Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 214-221.	1.3	11
164	Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials. Neurobiology of Aging, 2016, 39, S22.	3.1	0
165	Alzheimer's drug development pipeline: 2016. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 222-232.	3.7	87
166	Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	6.2	323
167	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 1131-1139.	2.6	34
168	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 4.	6.2	134
169	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
170	Dextromethorphan-Quinidine for Agitation in Alzheimer Disease—Reply. JAMA - Journal of the American Medical Association, 2016, 315, 1166.	7.4	2
171	Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimer's and Dementia, 2016, 12, 262-271.	0.8	50
172	A practical algorithm for managing Alzheimer's disease: what, when, and why?. Annals of Clinical and Translational Neurology, 2015, 2, 307-323.	3.7	68
173	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	30.5	1,210
174	Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440). American Journal of Geriatric Psychiatry, 2015, 23, S164-S165.	1.2	5
175	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 205-214.	2.6	57
176	Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. Journal of the American Geriatrics Society, 2015, 63, 1448-1452.	2.6	30
177	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Frontiers in Neurology, 2015, 6, 186.	2.4	22
178	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 2015, 12, 712-722.	1.4	134
179	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics, 2015, 27, 7-17.	1.0	244
180	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain, 2015, 138, 1036-1045.	7.6	67

#	ARTICLE	IF	CITATIONS
181	Skin reactions at the application site of rivastigmine patch (4.6Âmg/24Âh, 9.5Âmg/24Âh or 13.3Âmg/24Âh): a qualitative analysis of clinical studies in patients with Alzheimer's disease. International Journal of Clinical Practice, 2015, 69, 518-530.	1.7	15
182	Apathy in Neurodegenerative Diseases. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 159-173.	2.3	46
183	Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimer's Research and Therapy, 2015, 7, 9.	6.2	8
184	Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia. JAMA - Journal of the American Medical Association, 2015, 314, 1242.	7.4	155
185	Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimer's Research and Therapy, 2015, 7, 39.	6.2	19
186	Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimer's Research and Therapy, 2015, 7, 43.	6.2	25
187	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 455-461.	0.8	9
188	Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Review of Clinical Pharmacology, 2014, 7, 161-165.	3.1	27
189	The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 509-516.	1.3	50
190	Challenges and Opportunities to Conduct Global Alzheimer's Disease Clinical Trials. , 2014, , 61-75.		0
191	Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. International Psychogeriatrics, 2014, 26, 1871-1874.	1.0	4
192	The "Alzheimer's Type" Profile of Semantic Clustering in Amnesic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2014, 20, 402-412.	1.8	16
193	Risk Factors for Behavioral Abnormalities in Mild Cognitive Impairment and Mild Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 315-326.	1.5	67
194	Higher Working Memory Predicts Slower Functional Decline in Autopsy-Confirmed Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 38, 224-233.	1.5	22
195	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, The, 2014, 383, 533-540.	13.7	756
196	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
197	Overcoming obstacles to repurposing for neurodegenerative disease. Annals of Clinical and Translational Neurology, 2014, 1, 512-518.	3.7	43
198	Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia. Journal of Alzheimer's Disease, 2014, 43, 949-955.	2.6	63

#	ARTICLE	IF	CITATIONS
199	Alzheimer's disease drug-development pipeline: few candidates, frequent failures. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 37.	6.2	1,398
200	Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. <i>Translational Neurodegeneration</i> , 2014, 3, 12.	8.0	16
201	Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 335-343.	1.3	32
202	Evaluating the cognitive effects of donepezil 23â€‰mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. <i>BMC Geriatrics</i> , 2013, 13, 56.	2.7	23
203	Alzheimer's disease drug development: translational neuroscience strategies. <i>CNS Spectrums</i> , 2013, 18, 128-138.	1.2	23
204	The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. <i>Neurobiology of Aging</i> , 2013, 34, 1913-1920.	3.1	53
205	Alzheimer's disease biomarkers: Correspondence between human studies and animal models. <i>Neurobiology of Disease</i> , 2013, 56, 116-130.	4.4	20
206	The Cleveland Clinic Lou Ruvo Center for Brain Health: Keeping Memory Alive. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 103-109.	2.6	7
207	Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. <i>Neurobiology of Aging</i> , 2013, 34, 169-183.	3.1	74
208	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013, 34, 62-72.	3.1	49
209	Subscale Validation of the Neuropsychiatric Inventory Questionnaire: Comparison of Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center Cohorts. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 607-622.	1.2	42
210	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30</i>	0.8	48
211	Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 295-299.	2.2	66
212	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013, 9, 176-188.	0.8	58
213	The dementia and disability project in Thai elderly: rationale, design, methodology and early results. <i>BMC Neurology</i> , 2013, 13, 3.	1.8	13
214	High-Dose Donepezil (23Âmg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 294-301.	3.9	53
215	International Work Group Criteria for the Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 363-368.	2.5	72
216	Clinical Trials in Predementia Stages of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 439-457.	2.5	46

#	ARTICLE	IF	CITATIONS
217	A Review: Treatment of Alzheimer's Disease Discovered in Repurposed Agents. Dementia and Geriatric Cognitive Disorders, 2013, 35, 1-22.	1.5	71
218	Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 583-591.	1.9	12
219	Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study. Alzheimer Disease and Associated Disorders, 2013, 27, 174-181.	1.3	22
220	Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. International Psychogeriatrics, 2013, 25, 431-438.	1.0	10
221	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics, 2013, 25, 707-719.	1.0	43
222	The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics, 2013, 25, 175-177.	1.0	14
223	Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications. Current Topics in Medicinal Chemistry, 2013, 13, 2306-2327.	2.1	60
224	Alzheimer's disease biomarkers in animal models: closing the translational gap. American Journal of Neurodegenerative Disease, 2013, 2, 108-20.	0.1	19
225	Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006395-a006395.	6.2	57
226	Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm ²) in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 341-353.	1.5	88
227	Reviewing the Role of Donepezil in the Treatment of Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 773-781.	1.4	26
228	Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 1-5.	1.5	38
229	Age and Rate of Cognitive Decline in Alzheimer Disease. Archives of Neurology, 2012, 69, 901-5.	4.5	68
230	Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 421-432.	1.9	23
231	Advances in designs for Alzheimer's disease clinical trials. American Journal of Neurodegenerative Disease, 2012, 1, 205-16.	0.1	26
232	Globalization of Alzheimer's disease clinical trials. Alzheimer's Research and Therapy, 2011, 3, 24.	6.2	31
233	Biomarkers in Alzheimer's disease drug development. Alzheimer's and Dementia, 2011, 7, e13-44.	0.8	104
234	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676

#	ARTICLE	IF	CITATIONS
235	Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurology, 2011, 11, 21.	1.8	51
236	Alzheimer's Disease Clinical Trials: Changing the Paradigm. Current Psychiatry Reports, 2011, 13, 437-442.	4.5	11
237	Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry, 2011, 26, 150-157.	2.7	46
238	Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. Archives of General Psychiatry, 2011, 68, 853.	12.3	183
239	The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain, 2011, 134, 3146-3166.	7.6	174
240	Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. International Psychogeriatrics, 2010, 22, 973-983.	1.0	37
241	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.	2.6	347
242	Commentary on: <i>L-Methylfolate, Methylcobalamine, and N-Acetylcysteine in the Treatment of Alzheimer's Disease-Related Cognitive Decline</i>. CNS Spectrums, 2010, 15, 7-7.	1.2	1
243	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping, 2010, 31, 786-797.	3.6	91
244	Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect. Annals of Neurology, 2010, 68, 693-702.	5.3	324
245	Mary S. Easton Center of Alzheimer's Disease Research at UCLA: Advancing the Therapeutic Imperative. Journal of Alzheimer's Disease, 2010, 19, 375-388.	2.6	2
246	Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 2010, 22, 346-372.	1.0	295
247	What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?. Biological Psychiatry, 2010, 68, 876-878.	1.3	60
248	Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiology of Aging, 2010, 31, 1481-1492.	3.1	51
249	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging, 2010, 31, 1284-1303.	3.1	127
250	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. NeuroImage, 2010, 51, 488-499.	4.2	78
251	Apathy Symptom Profile and Behavioral Associations in Frontotemporal Dementia vs Dementia of Alzheimer Type. Archives of Neurology, 2009, 66, 888-93.	4.5	119
252	Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology, 2009, 5, 245-255.	10.1	336

#	ARTICLE	IF	CITATIONS
253	Defining and labeling disease-modifying treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009, 5, 406-418.	0.8	59
254	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: Utility and incentives. , 2009, 5, 108-113.		3
255	The Alzheimer's Disease Centers' Uniform Data Set (UDS). <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 91-101.	1.3	684
256	Neuropsychiatric Manifestations in Mild Cognitive Impairment: A Systematic Review of the Literature. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 115-126.	1.5	333
257	Optimizing phase II of drug development for disease-modifying compounds. , 2008, 4, S15-S20.		24
258	Controversies in Alzheimer's disease drug development. <i>International Review of Psychiatry</i> , 2008, 20, 389-395.	2.8	23
259	Progress in Neurotherapeutics and Neuropsychopharmacology 2008. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2008, 3, .	0.0	0
260	Integrating Symptomatic- and Disease-Modifying Treatments. <i>CNS Spectrums</i> , 2008, 13, 28-30.	1.2	3
261	Elderly Patients With Dementia-Related Symptoms of Severe Agitation and Aggression. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 889-898.	2.2	202
262	Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. <i>CNS Spectrums</i> , 2008, 13, 4-5.	1.2	10
263	Disease-modifying therapies for Alzheimer disease. <i>Neurology</i> , 2007, 69, 1622-1634.	1.1	261
264	Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. <i>Brain</i> , 2007, 130, 1767-1776.	7.6	229
265	Positron Emission Tomography Metabolic Correlates of Apathy in Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 1015.	4.5	185
266	Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. <i>Neurology</i> , 2007, 68, 1356-1363.	1.1	197
267	Clinical Trials in Dementia. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 39-78.	0.0	0
268	Progress in Neurotherapeutics and Neuropsychopharmacology 2007. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 1-12.	0.0	0
269	Neuropsychiatric Symptoms Are Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 253-259.	1.5	176
270	Structural Correlates of Apathy in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 91-97.	1.5	159

#	ARTICLE	IF	CITATIONS
271	A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry, 2007, 22, 456-467.	2.7	273
272	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	3.9	2,497
273	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology, The, 2007, 6, 501-512.	10.2	314
274	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
275	Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Reviews in Neurological Diseases, 2007, 4, 57-62.	0.3	15
276	Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. Psychopharmacology Bulletin, 2007, 40, 89-98.	0.0	7
277	Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders. American Journal of Geriatric Psychiatry, 2006, 14, 605-612.	1.2	135
278	Clinical evaluation as a biomarker for Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 327-337.	2.6	13
279	ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Disease and Associated Disorders, 2006, 20, S109-S123.	1.3	60
280	Neuropathologic Correlates of Activities of Daily Living in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 56-59.	1.3	49
281	The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders, 2006, 20, 210-216.	1.3	743
282	ADCS Prevention Instrument Project: Behavioral Measures in Primary Prevention Trials. Alzheimer Disease and Associated Disorders, 2006, 20, S147-S151.	1.3	12
283	Defining and Diagnosing Involuntary Emotional Expression Disorder. CNS Spectrums, 2006, 11, 1-11.	1.2	168
284	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Reviews Drug Discovery, 2006, 5, 64-74.	46.4	39
285	Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps. Archives of Neurology, 2006, 63, 693.	4.5	490
286	Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 2006, 67, 57-63.	1.1	201
287	Neuropathologic Correlates of Apathy in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 144-147.	1.5	128
288	Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 702-707.	7.1	221

#	ARTICLE	IF	CITATIONS
289	Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2005, 17, 81-90.	1.0	37
290	The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 695-699.	2.6	16,505
291	Behavioural changes and psychological symptoms in dementia disorders. <i>Lancet Neurology</i> , The, 2005, 4, 735-742.	10.2	192
292	Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy. <i>Archives of Neurology</i> , 2005, 62, 721.	4.5	109
293	Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 469-474.	1.2	190
294	Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 469-474.	1.2	134
295	Executive Dysfunction in Alzheimer Disease. <i>Archives of Neurology</i> , 2004, 61, 556.	4.5	163
296	Association of the Serotonin Transporter and Receptor Gene Polymorphisms in Neuropsychiatric Symptoms in Alzheimer Disease. <i>Archives of Neurology</i> , 2004, 61, 1249-53.	4.5	127
297	Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease. <i>American Journal of Psychiatry</i> , 2004, 161, 532-538.	7.2	155
298	Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 32-35.	2.3	63
299	Fluctuations in cognitive function in dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 266.	10.2	17
300	Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 56-67.	27.0	1,221
301	Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 112-119.	2.3	39
302	Mild Cognitive Impairment is Associated With Characteristic Neuropsychiatric Symptoms. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 17-21.	1.3	229
303	Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia. <i>Current Alzheimer Research</i> , 2004, 1, 323-328.	1.4	13
304	Treatment of Alzheimer's disease: current and future therapeutic approaches. <i>Reviews in Neurological Diseases</i> , 2004, 1, 60-9.	0.3	59
305	Toward a molecular neuropsychiatry of neurodegenerative diseases. <i>Annals of Neurology</i> , 2003, 54, 147-154.	5.3	87
306	The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. <i>Journal of Sleep Research</i> , 2003, 12, 331-337.	3.2	140

#	ARTICLE	IF	CITATIONS
307	Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. <i>Molecular Genetics and Metabolism</i> , 2003, 80, 350-355.	1.1	50
308	Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 99-106.	2.8	23
309	A New Measurement of Activities of Daily Living for Thai Elderly With Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 135-148.	1.0	24
310	Delusional Thoughts and Regional Frontal/Temporal Cortex Metabolism in Alzheimer's Disease. <i>American Journal of Psychiatry</i> , 2003, 160, 341-349.	7.2	158
311	Alzheimer's disease: From molecular biology to neuropsychiatry. <i>Seminars in Clinical Neuropsychiatry</i> , 2003, 8, 31-36.	1.9	12
312	Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 131-45.	1.2	49
313	Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2335.	7.4	379
314	Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 67-73.	1.5	111
315	Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002, 57, M173-M177.	3.6	213
316	A Videotape-Based Training Method for Improving the Detection of Depression in Residents of Long-Term Care Facilities. <i>Gerontologist</i> , The, 2002, 42, 114-121.	3.9	109
317	Apathy and executive function in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 373-381.	1.8	141
318	Provisional Diagnostic Criteria for Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2002, 10, 125-128.	1.2	269
319	Guidelines for managing Alzheimer's disease: part I. Assessment. <i>American Family Physician</i> , 2002, 65, 2263-72.	0.1	61
320	Guidelines for managing Alzheimer's disease: Part II. Treatment. <i>American Family Physician</i> , 2002, 65, 2525-34.	0.1	58
321	Behavioral Disorders and Caregivers' Reaction in Taiwanese Patients With Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2001, 13, 121-128.	1.0	109
322	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. <i>Movement Disorders</i> , 2001, 16, 1098-1104.	3.9	42
323	Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 789-793.	2.7	116
324	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. <i>Annals of Neurology</i> , 2001, 49, 355-361.	5.3	256

#	ARTICLE	IF	CITATIONS
325	Geriatric Neuropsychopharmacology: Unmet Needs. Psychogeriatrics, 2001, 1, 14-26.	1.2	0
326	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting. Journal of the American Geriatrics Society, 2001, 49, 1590-1599.	2.6	328
327	Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 101-108.	2.3	52
328	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Annals of Neurology, 2001, 49, 355-361.	5.3	152
329	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting. Journal of the American Geriatrics Society, 2001, 49, 1590-1599.	2.6	8
330	Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 209-218.	1.8	61
331	Left Frontotemporal Hypoperfusion Is Associated With Aggression in Patients With Dementia. Archives of Neurology, 2000, 57, 861.	4.5	139
332	Utilization of Alzheimer's disease community resources by Asian-Americans in California. International Journal of Geriatric Psychiatry, 2000, 15, 838-847.	2.7	49
333	Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 233-239.	1.8	1,342
334	Functional correlates of musical and visual ability in frontotemporal dementia. British Journal of Psychiatry, 2000, 176, 458-463.	2.8	235
335	Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiology of Aging, 2000, 21, 845-861.	3.1	204
336	Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. CNS Drugs, 2000, 13, 385-395.	5.9	13
337	The Use of the Neuropsychiatric Inventory in Nursing Home Residents: Characterization and Measurement. American Journal of Geriatric Psychiatry, 2000, 8, 75-83.	1.2	382
338	Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. International Journal of Neuropsychopharmacology, 1999, 2, 59-66.	2.1	7
339	The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease. Archives of Neurology, 1999, 56, 1388.	4.5	237
340	Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opinion on Investigational Drugs, 1999, 8, 463-471.	4.1	21
341	Neuropsychiatric aspects of dementia with lewy bodies. Current Psychiatry Reports, 1999, 1, 85-92.	4.5	22
342	Measuring Outcomes in Alzheimer's Disease Research. Disease Management and Health Outcomes, 1999, 5, 1-12.	0.4	5

#	ARTICLE	IF	CITATIONS
343	Gender-Related Cognitive Deficits in Alzheimer's Disease. International Psychogeriatrics, 1999, 11, 117-122.	1.0	49
344	Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. Neurocase, 1999, 5, 181-188.	0.6	10
345	Principles of Neuropsychiatry: Towards a Neuropsychiatric Epistemology. Neurocase, 1999, 5, 181-188.	0.6	0
346	Apathy Is Not Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 314-319.	1.8	554
347	Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: The Neuropsychiatric Inventory Caregiver Distress Scale. Journal of the American Geriatrics Society, 1998, 46, 210-215.	2.6	489
348	Behavioral Disorders in Alzheimer Disease: A Transcultural Perspective. Archives of Neurology, 1998, 55, 539.	4.5	100
349	Anti-dementia drugs: what difference do they make?. Reviews in Clinical Gerontology, 1998, 8, 279-280.	0.5	0
350	Treatment of Depression in the Patient with Parkinson's Disease. Clinical Geriatrics, 1998, 6, 34-46.	0.0	1
351	Barriers to Behavioral Research on Dementia. International Psychogeriatrics, 1996, 8, 21-23.	1.0	1
352	Neuropsychiatric Assessment and Intervention in Alzheimer's Disease. International Psychogeriatrics, 1996, 8, 25-30.	1.0	10
353	Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia. Journal of the International Neuropsychological Society, 1996, 2, 505-510.	1.8	134
354	Quantitative EEG in Frontotemporal Dementia. Clinical EEG (electroencephalography), 1996, 27, 61-68.	0.9	62
355	The spectrum of behavioral changes in Alzheimer's disease. Neurology, 1996, 46, 130-135.	1.1	998
356	Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 1-6.	2.3	185
357	Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression. Neurocase, 1996, 2, 455-459.	0.6	4
358	Depression and Reversible Dementia in an HIV-1 Seropositive Individual: Implications for the Dementia Syndrome of Depression. Neurocase, 1996, 2, 455-459.	0.6	0
359	Neurobehavioural examination of frontal lobe functions. Aphasiology, 1995, 9, 181-192.	2.2	16
360	The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. European Journal of Haematology, 1995, 54, 245-253.	2.2	101

#	ARTICLE	IF	CITATIONS
361	Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. American Journal of Geriatric Psychiatry, 1994, 2, 200-209.	1.2	9
362	Assessment of Cognitive, Psychiatric, and Behavioral Disturbances in Patients with Dementia: The Neurobehavioral Rating Scale. Journal of the American Geriatrics Society, 1992, 40, 549-555.	2.6	99
363	Behavioral Complications of Drug Treatment of Parkinson's Disease. Journal of the American Geriatrics Society, 1991, 39, 708-716.	2.6	154
364	Speech and language alterations in dementia syndromes: Characteristics and treatment. Aphasiology, 1990, 4, 339-352.	2.2	27
365	Psychological Dysfunction Accompanying Subcortical Dementias. Annual Review of Medicine, 1988, 39, 53-61.	12.2	86
366	Altered Behavior Associated with Damage to the Ventromedial Hypothalamus: A Distinctive Syndrome. Behavioural Neurology, 1988, 1, 49-58.	2.1	29
367	Atypical Dementia Syndrome in an Elderly Man. Journal of the American Geriatrics Society, 1987, 35, 1116-1126.	2.6	3
368	De Cl�rambault's Syndrome in Organic Affective Disorder. British Journal of Psychiatry, 1987, 151, 404-407.	2.8	37
369	Treatment of Alzheimer's disease. , 0, , 415-424.		3